Evaluating a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin
NCT ID: NCT02140489
Last Updated: 2014-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
30 participants
INTERVENTIONAL
2014-02-28
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine
NCT02387619
Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe
NCT02127320
A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin
NCT02569814
Pharmacokinetic Drug Interaction Between Rosuvastatin and Valsartan
NCT01609907
The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers
NCT03247140
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sequence 1
amosartan → rosuvastatin → amosartan and rosuvastatin
amosartan
rosuvastatin
amosartan and rosuvastatin
Sequence 2
rosuvastatin → amosartan and rosuvastatin → amosartan
amosartan
rosuvastatin
amosartan and rosuvastatin
Sequence 3
amosartan and rosuvastatin → amosartan → rosuvastatin
amosartan
rosuvastatin
amosartan and rosuvastatin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
amosartan
rosuvastatin
amosartan and rosuvastatin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 19 and 55
* Signed informed consent
Exclusion Criteria
* Has a history of hypersensitivity to IP ingredients
19 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanmi Pharmaceutical Company Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
JaeWook Ko, M.D.
Role: PRINCIPAL_INVESTIGATOR
Samsung Seoul Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samgsung Seoul Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM-ALRO-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.